Earnings summaries and quarterly performance for Zomedica.
Executive leadership at Zomedica.
Board of directors at Zomedica.
Research analysts covering Zomedica.
Recent press releases and 8-K filings for ZOMDF.
Zomedica Announces Q3 2025 Financial Results
ZOMDF
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Zomedica Corp. reported record quarterly revenue of $8.1 million for the third quarter ended September 30, 2025, marking a 16% increase compared to the same period in the prior year and the 19th straight quarter of year-over-year revenue growth.
- The company achieved a gross margin of 67% for the third quarter of 2025.
- Zomedica's net loss decreased by 9% to $6.1 million for Q3 2025, and its Adjusted Non-GAAP EBITDA loss decreased by 14% to $3.7 million compared to the third quarter of 2024.
- As of September 30, 2025, Zomedica maintained $54.4 million in cash, cash equivalents, and available-for-sale securities.
- Total operating expenses for the quarter ended September 30, 2025, were $12.0 million, a 4% decrease from the prior year, driven by a $0.5 million reduction in OPEX.
Nov 4, 2025, 9:25 PM
Quarterly earnings call transcripts for Zomedica.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more